Skip to main content
padlock icon - secure page this page is secure

Free Content Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis

Download Article:
 Download
(PDF 123.3 kb)
 
SETTING: A community-based treatment program for multidrug-resistant tuberculosis (MDR-TB) in an urban shantytown of Lima, Peru.

OBJECTIVES: To ascertain the occurrence of serious adverse effects associated with therapy for MDR-TB in northern Lima, Peru, where therapy was individualized according to drug-susceptibility testing of patients’ infecting strains and delivered through a community-based program.

DESIGN: A retrospective record review of 60 patients who had received individualized therapy for MDR-TB between September 1996 and October 1998.

RESULTS: Although adverse effects were common, they occurred less frequently than previously reported in the literature and were rarely life-threatening. Effects occurring most frequently in this population included: mild gastritis (100%), dermatological effects (43.3%), peripheral neuropathy (16.7%), depression (18.3%), and anxiety (11.7%). These effects never resulted in the discontinuation of anti-tuberculosis therapy, and only occasionally resulted in the suspension of an agent (11.7%).

CONCLUSION: In young patients with little comorbid disease, multidrug, long-course regimens rarely caused life-threatening adverse effects. Common side effects may be managed successfully on an out-patient basis through a community-based treatment program in conjunction with MDR-TB experts, even in resource-poor settings. The very low rate of default in this cohort offers hope that strategies to manage the adverse effects may reduce the incidence of abandonment of therapy and increase rates of cure.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: adverse effects; antimicrobial resistance; tuberculosis

Document Type: Regular Paper

Affiliations: 1: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Brigham and WomenÕs Hospital, Boston, Massachusetts, USA 2: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Department of Population and International Health, Harvard School of Public Health, Boston, Massachusetts, USA 3: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Socios En Salud—Sucursal Peru/Partners In Health, Carabayllo, Peru 4: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA 5: Socios En Salud—Sucursal Peru/Partners In Health, Carabayllo, Peru 6: Servicio de Neurología, Instituto Nacional de Salud Mental ‘Honorio Delgado-Hideyo Noguchi’, Lima, Peru 7: National Tuberculosis Program, Lima, Peru and Hospital Sergio E. Bernales, Comas, Peru

Publication date: July 1, 2001

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more